SB
PCRX icon

Suntrust Banks’s Pacira BioSciences PCRX Stock Holding History

Suntrust Banks’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-14,328
Closed -$684K – 1305
2017
Q2 		$684K Sell
14,328
-109
-0.8% -$5.06K ﹤0.01% 755
2017
Q1 		$658K Buy
14,437
+2,385
+20% +$103K ﹤0.01% 761
2016
Q4 		$388K Sell
12,052
-91
-0.7% -$3.04K ﹤0.01% 1121
2016
Q3 		$415K Sell
12,143
-7,037
-37% -$276K ﹤0.01% 1039
2016
Q2 		$646K Buy
19,180
+13,448
+235% +$661K ﹤0.01% 856
2016
Q1 		$303K Buy
+5,732
New +$335K ﹤0.01% 1127
2014
Q2 		– Sell
-20,850
Closed -$1.46M – 1612
2014
Q1 		$1.46M Buy
+20,850
New +$1.42M 0.01% 785

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return